MX2014011167A - Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada. - Google Patents

Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.

Info

Publication number
MX2014011167A
MX2014011167A MX2014011167A MX2014011167A MX2014011167A MX 2014011167 A MX2014011167 A MX 2014011167A MX 2014011167 A MX2014011167 A MX 2014011167A MX 2014011167 A MX2014011167 A MX 2014011167A MX 2014011167 A MX2014011167 A MX 2014011167A
Authority
MX
Mexico
Prior art keywords
rosuvastatin
metformin
layer
release
granules
Prior art date
Application number
MX2014011167A
Other languages
English (en)
Spanish (es)
Inventor
Marie Charmaine Dias
Original Assignee
Althera Life Sciencies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Althera Life Sciencies Llc filed Critical Althera Life Sciencies Llc
Publication of MX2014011167A publication Critical patent/MX2014011167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2014011167A 2012-03-19 2013-03-15 Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada. MX2014011167A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612563P 2012-03-19 2012-03-19
US201261640971P 2012-05-01 2012-05-01
PCT/US2013/031986 WO2013142314A1 (fr) 2012-03-19 2013-03-15 Formulation de comprimé oral constituée de rosuvastatine à libération immédiate et de metformine à libération prolongée

Publications (1)

Publication Number Publication Date
MX2014011167A true MX2014011167A (es) 2014-11-14

Family

ID=49223247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011167A MX2014011167A (es) 2012-03-19 2013-03-15 Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.

Country Status (3)

Country Link
EP (1) EP2844067A4 (fr)
MX (1) MX2014011167A (fr)
WO (1) WO2013142314A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1510208A1 (fr) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
CA2600736A1 (fr) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Systeme d'administration pour de multiples medicaments
EP1970053A1 (fr) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Composition pharmaceutique
KR101573889B1 (ko) * 2009-10-09 2015-12-04 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
CN106890149A (zh) * 2009-12-30 2017-06-27 有限公司公元前世界医药 包括二甲双胍和瑞舒伐他汀的药物组合物

Also Published As

Publication number Publication date
EP2844067A1 (fr) 2015-03-11
EP2844067A4 (fr) 2015-11-25
WO2013142314A1 (fr) 2013-09-26

Similar Documents

Publication Publication Date Title
CA2615496C (fr) Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
AU732465B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US20070281021A1 (en) Sustained release formulation of naltrexone
KR20020057994A (ko) 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
ZA200408441B (en) High drug load tablet
US20040202716A1 (en) Composition
RU2664422C2 (ru) Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения
Zhong et al. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis
WO2013166117A1 (fr) Formulation de comprimé oral constituée d'une combinaison fixe de rosuvastatine et d'ézétimibe pour le traitement de l'hyperlipidémie et de maladies cardiovasculaires
EP2061448A2 (fr) Formulation à libération prolongée de naltréxone
IL295519A (en) Mazindol immediate-release/delayed-release multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder
MX2011002227A (es) Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa.
MX2014011167A (es) Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.
US20200222401A1 (en) Oral Tablet Formulation Consisting of Immediate Release Rosuvastatin and Extended Release Metformin
KR102409102B1 (ko) 제약 조성물
WO2019018158A1 (fr) Compositions pharmaceutiques
CN108366969A (zh) 萘普生钠的改性释放制剂
KR102496851B1 (ko) 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법
NZ567268A (en) Retard formulation for pralnacasan
US9744135B2 (en) Fast disintegrating compositions and tablets thereof
WO2022251563A1 (fr) Formulations pédiatriques de citrate ferrique
WO2022228735A1 (fr) Composition pharmaceutique comprenant une combinaison de sitagliptine et de metformine et son procédé de préparation
WO2015189807A1 (fr) Formulations de comprimés bicouches de cyclophosphamide et de capécitabine pour administration métronomique hautement fractionnée de celles-ci
WO2023012817A1 (fr) Composition pharmaceutique comprenant une combinaison de dapagliflozine et de sitagliptine
Day Oral antidiabetic agents: Is it time to combine therapies?

Legal Events

Date Code Title Description
FG Grant or registration